Ketamine With a History of Addiction: Can You Still Have It?

by | Oct 4, 2026 | Blogs, Patient Guides | 0 comments

The number has been on the back of an envelope for two weeks.

Every time you pick up the phone you get as far as imagining one question, the one about past substance use, and you set it back down. You have already decided how the call ends.

So you search instead for ketamine with a history of addiction, bracing for a page that tells you no. This is not that page, and it does not tell you yes either.

If you are in crisis, call or text 988 (Suicide & Crisis Lifeline).
SAMHSA National Helpline: 1-800-662-HELP (4357) – free, confidential, 24/7, in English and Spanish, for treatment referral and information.
If someone may be overdosing, call 911. Naloxone reverses opioid overdose and is available without a prescription in Texas.
Stopping alcohol or benzodiazepines suddenly can be dangerous. Talk with a clinician before you stop, and go to an emergency room if you develop shaking, confusion, or seizures.

We are an outpatient practice and cannot provide emergency care. Our Fort Worth office: 817-659-7344.

Is ketamine addictive, and what does Schedule III mean?

Ketamine is a Schedule III controlled substance, listed by name at 21 CFR 1308.13. The KETALAR label says the same, and its section on abuse speaks to your question: “Individuals with a history of drug abuse or dependence may be at greater risk for abuse and misuse of KETALAR.”

That label also reports tolerance and physical dependence with prolonged ketamine use, and withdrawal symptoms after stopping frequent, large doses taken over long periods. Those findings describe heavy use rather than a supervised course, but they are part of why a history like yours changes how carefully this is approached.

The National Institute on Drug Abuse answer is careful: regular use in humans “is associated with symptoms of addiction,” while “more research is needed to determine how addictive ketamine might be.”

Can you have ketamine with a history of addiction? What the guidelines say

Use of intravenous ketamine for depression is off-label, as our ketamine infusion therapy page states.

The 2021 Canadian Network for Mood and Anxiety Treatments task force lists “substance use/dependence” among the relative contraindications to ketamine. Relative means weighed, not automatic.

A 2021 international expert opinion in the American Journal of Psychiatry does not include substance use history among exclusions, and writes that “current psychiatric comorbidities need not be exclusionary as long as major depressive symptoms are the principal focus of clinical concern.”

The same expert group notes that adults with depression and co-occurring substance use disorders have not been sufficiently studied, and that the available evidence does not rule out misuse risk when ketamine is used for treatment-resistant depression.

So it gets assessed, and watched more closely afterward. It is not an automatic no.

What gets assessed before an infusion series

One question sits underneath the rest: is the depression a separate  condition, or is it produced or amplified by the substance use? Heavy alcohol use, stimulant withdrawal, and sedatives can all generate depressive symptoms that look like major depression and often lift with sustained abstinence. Sorting that out is a common reason an assessment lands on “not yet” rather than “no.”

What gets asked about Why it matters
Which substances, how much, how recently Guidance treats substance use and dependence as a relative contraindication: weighed, not decisive
Whether any use is current It changes what is reasonable now, and what may need to happen first
Heart and blood pressure history Ketamine can temporarily raise blood pressure; the same guidance lists poorly controlled hypertension and unstable cardiovascular conditions as relative contraindications, and suggests an ECG if indicated by history or exam
What happens after a first series Maintenance patients should be reassessed regularly for urinary symptoms, cognitive effects, and substance misuse or dependence

 

That guidance may also recommend a urine drug screen if indicated by history or exam. When clinically indicated, your clinician will discuss whether urine drug screening is needed and how it can be arranged. Clinical screening and monitoring are distinct from testing or evaluations requested for employment or legal proceedings.

The assessment only works on true information. Saying it out loud is not the same as being turned away.

If you are reading this while still drinking or still using, that belongs in the conversation rather than counting as a mark against you. One thing is urgent, though: stopping alcohol or benzodiazepines suddenly can be life-threatening, and some people need medically supervised withdrawal. The evaluation helps determine whether outpatient care is appropriate or a higher level of medically supervised withdrawal care is needed. If you develop shaking, confusion, or seizures after cutting down, go to an emergency room.

The safeguards that matter most if this is your history

Ketamine has potential for misuse and dependence. At our practice, IV ketamine is administered only as a supervised, time-limited, in-office treatment. We do not provide ketamine for at-home use.

From that page:

  • Infusions are performed in the office, with a monitored recovery period afterward.
  • A responsible adult age 18 or older must bring you, stay in the waiting area throughout your visit, and drive you home. Discharge alone, or to a rideshare or taxi, is not permitted.
  • Do not drive or operate machinery for at least 24 hours after your infusion. Follow the clinic’s post-treatment instructions concerning alcohol, recreational drugs, sedating medications and activities requiring unimpaired judgment or coordination.
  • You sign a consent form beforehand and can withdraw it at any time, including during an infusion.

Why is at-home ketamine riskier?

In an analysis of 25 studies, NIDA reports, “medically unsupervised ketamine use was associated with related substance use disorder symptoms, memory loss, depression, and anxiety.” NIDA adds that laboratory research and a few human studies suggest use outside a clinical setting “can lead to cravings as well as symptoms of withdrawal,” though more research is needed.

The FDA warned in October 2023 about potential risks of compounded ketamine products, including oral formulations, for psychiatric disorders (archived FDA guidance).

Ketamine: Off-Label Use and Individualized Evaluation

The Institute provides outpatient addiction treatment.

When considering IV ketamine for a psychiatric condition, we evaluate the whole person—including medical and psychiatric conditions, current and past substance use, treatment history, and individual circumstances. A history of addiction is an important part of this individualized evaluation and safety assessment.

How long does the benefit usually last?

Response and duration of benefit vary. Some patients improve quickly, but improvement may not be sustained without additional treatment. Any repeated or maintenance treatment is individualized according to clinical response, tolerability and the broader treatment plan. Discuss expectations and follow-up with your clinician.

Frequently asked questions

Will a history of addiction automatically disqualify me from ketamine treatment?
A substance use history is one of the things assessed before an infusion series, and the published guidance stops short of a rule. The 2021 Canadian task force calls it a relative contraindication; the expert opinion does not list it among absolute exclusions. That leaves no automatic yes and no automatic no. Use of IV ketamine for depression is off-label.

I am in recovery. Would an infusion count against my sobriety?
Recovery communities answer that differently, and nobody at a clinic gets to settle it for you. What can be said is that this is a prescribed medication, given under supervision in an office, with nothing dispensed to take home. Put the question to your clinician, and to whoever supports your recovery, before a first infusion.

Does the Institute Provide Addiction Treatment as Well as IV Ketamine Treatment?
Yes. The Institute provides outpatient addiction care as part of its comprehensive psychiatric services.

Addiction treatment is individualized and is separate from the decision to use IV ketamine.

A history of substance use or addiction does not automatically determine whether a patient is a candidate for IV ketamine. Current substance use, psychiatric history, medical history, previous treatment, medications, and other safety considerations are evaluated as part of the clinical assessment.

IV ketamine may be considered for appropriate psychiatric indications after individualized evaluation. Its use for psychiatric conditions is off-label. The evaluation takes into account medical and psychiatric conditions, current and past substance use, treatment history, and individual circumstances.

The bottom line

Ketamine is a Schedule III controlled substance, and its use for depression is off-label. A substance use history is part of what gets assessed beforehand, and published guidance treats it as a relative contraindication rather than an automatic bar. Nobody can hand you a yes or a no from a distance, but the structure can be described: given and monitored in the office, nothing dispensed to take home, someone you trust driving you home. If you have not called because you assumed the answer was decided, it is not.

Talk with us

If you are in Fort Worth or the surrounding North Texas area and what you have read here sounds familiar, we would be glad to talk it through with you. The Institute for Advanced Psychiatry is an outpatient practice at 6800 Harris Parkway, Suite 100, treating adults 18 and older. You can request an appointment or call 817-659-7344.

If you are in crisis or thinking about harming yourself, please do not wait for an appointment. Call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7, or go to your nearest emergency room.

If you are in crisis, call or text 988 (Suicide & Crisis Lifeline).
SAMHSA National Helpline: 1-800-662-HELP (4357) – free, confidential, 24/7, in English and Spanish, for treatment referral and information.
If someone may be overdosing, call 911. Naloxone reverses opioid overdose and is available without a prescription in Texas.
Stopping alcohol or benzodiazepines suddenly can be dangerous. Talk with a clinician before you stop, and go to an emergency room if you develop shaking, confusion, or seizures.

Sources

  1. Institute for Advanced Psychiatry. “Ketamine Infusion Therapy.” Accessed 2026. https://www.psychiatryfortworth.com/services/ketamine-infusion-therapy/
  2. Electronic Code of Federal Regulations. “21 CFR 1308.13 – Schedule III.” 2024 edition. https://www.ecfr.gov/current/title-21/section-1308.13
  3. DailyMed / U.S. National Library of Medicine. “KETALAR – ketamine hydrochloride injection (FDA-approved prescribing information).” Revised March 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e8f864-8b8a-4e7e-8439-e510d3107063
  4. National Institute on Drug Abuse. “Ketamine (Research Topics).” Last updated April 9, 2024. https://nida.nih.gov/research-topics/ketamine
  5. National Institute on Drug Abuse. “Psychedelic and Dissociative Drugs (Research Topics).” Accessed 2026. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs
  6. Swainson J, et al. “The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.” Canadian Journal of Psychiatry. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC7918868/
  7. McIntyre RS, et al. “Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.” American Journal of Psychiatry. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC9635017/
  8. U.S. Food and Drug Administration. “FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders.” October 10, 2023. Archived FDA guidance, accessed 2026. https://web.archive.org/web/20260530025451/https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine
  9. National Institute on Drug Abuse. “Words Matter – Terms to Use and Avoid When Talking About Addiction.” Accessed 2026. https://nida.nih.gov/nidamed-medical-health-professionals/health-professions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction
  10. Substance Abuse and Mental Health Services Administration. “National Helpline.” Accessed 2026. https://www.samhsa.gov/find-help/helplines/national-helpline
  11. Institute for Advanced Psychiatry. “Diana Ghelber, MD.” Accessed 2026. https://www.psychiatryfortworth.com/providers/diana-ghelber-md/

Medical disclaimer

This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation for any individual. Reading it does not create a physician-patient relationship. Treatment decisions, including whether any medication or procedure is appropriate for you, should be made with a qualified clinician who knows your history. Do not start, stop, or change a psychiatric medication without talking to your prescriber. If you are experiencing a medical or mental health emergency, call 911 or 988.

Request an Appointment

Note: This form is for general inquiries only. For urgent mental health needs, please call us directly at 817-659-7344 or call 988 (Suicide & Crisis Lifeline).

By submitting, you agree to our Privacy Policy. We typically respond within 1 business day.